Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BioSante Pharma Reveals Positive Results Of Its Prostate Cancer Vaccine Study

RELATED NEWS
Trade BPAX now with 

Specialty pharmaceutical company BioSante Pharmaceuticals Inc (BPAX: Quote) Monday announced that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.

The results revealed that the GVAX Prostate cancer vaccine, used in treating metastatic castration-resistant prostate cancer patients in combination with ipilimumab, resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases.

The results further revealed that 23 percent of patients in the higher dose cohorts had confirmed partial PSA response of greater than 50 percent from baseline.

The study further concluded that there were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe.

Click here to receive FREE breaking news email alerts for ANI Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
While buying interest has remained somewhat subdued, stocks are seeing modest strength in mid-day trading on Thursday. The slim gains on the day have lifted the S&P 500 to a new record intraday high above the 1,990 level. New home sales in the U.S. showed a notable decrease in the month of June, according to a report released by the Commerce Department on Thursday, with the steep drop offsetting the jump seen in the previous month. After reporting a modest drop in first-time claims for U.S. unemployment benefits in the previous week, the Labor Department released a report on Thursday showing that initial jobless claims unexpectedly fell to their lowest level in over eight years in the week ended July 19th.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.